Immunization of mouse models of Alzheimer disease (AD) with amyloid-peptide (AB) reduces AB deposits and attenuates their memory and learning deficits. Recent clinical trials were halted due to meningoencephalitis, presumably induced by T cell mediated and/or Fc-mediated immune responses. Because injection of anti-AB F(ab') 2 antibodies also induces clearance of amyloid plaques in AD mouse models, we have tested a novel gene therapy modality where an adenoassociated virus (AAV) encoding anti-AB single-chain antibody (scFv) is injected into the corticohippocampal regions of AD mouse models. One year after injection, expression of scFv was readily detectable in the neurons of the hippocampus without discernible neurotoxicity. AD mouse models subjected to AAV injection had much less amyloid deposits at the injection sites than the mouse models subjected to PBS injection. Because the scFv lacks the Fc portion of the immunoglobulin molecule, this modality may be a feasible solution for AD without eliciting inflammation. D
Introduction
Alzheimer's disease (AD) is the most common cause of dementia after the age of 60. The pathological hallmarks of AD include deposition of amyloid h-peptide (Ah) in neuritic plaques and cerebral blood vessels, neurofibrillary tangles, and loss of neurons. Ah is derived from its precursor, APP, by proteolytic processing. Generation of Ah requires cleavage of APP by h-and g-secretase at the N-terminal and C-terminal end of Ah, respectively. The amyloid cascade hypothesis claims that accumulation of Ah in the brain is an initial and essential event in the pathogenesis of AD (Hardy and Selkoe, 2002) . This hypothesis is supported by increasing lines of evidence: (1) mutations in 3 different genes (APP, presenilin 1 and 2) implicated in the etiology of familial AD, have been shown to increase Ah production, particularly a longer form of Ah consisting of 42 amino acids (Ah1 -42) (Scheuner et al., 1996) ; (2) Ah1 -42 is considered to be highly amyloidogenic and oligomeric forms of Ah are neurotoxic (Lambert et al., 2001; Walsh et al., 2002) ; (3) patients with Down's syndrome (carrying three APP genes) develop AD pathology in their fourth or fifth decade of life; and (4) overexpression of the mutant forms of APP in transgenic mice leads to AD-like pathologies including amyloid plaques in the brain. While the causes of sporadic AD are not clear, based on the similarities in the pathological and clinical manifestations between familial and sporadic AD, it is widely considered that Ah also plays a pathogenetic role in sporadic AD.
The efficacy of Ah vaccination on AD treatment was first demonstrated in a transgenic mouse model of AD, where immunization of AD mouse models with synthetic Ah by repeated needle injection prevented or reduced Ah deposits and improved their memory and learning deficits (Janus et al., 2000; Morgan et al., 2000; Schenk et al., 1999) . These groundbreaking results prompted initiation of phase I/II clinical trials to evaluate the safety and tolerability of aggregated Ah (AN1792) vaccination. AD patients subjected to this treatment showed less decline among the patients with positive antiserum titers against Ah, compared with control patients in Disability Assessment for Dementia Scores, and no safety concerns arose during phase I clinical trial (Bayer et al., 2005) . The phase IIa clinical trial, however, was halted due to meningoencephalitis found in 6% of AD patients subjected to the vaccine trial (Orgogozo et al., 2003 
